Latent Tuberculosis Infection Resources
Updated March 2, 2021
Targeted Testing & Treatment Recommendations
CDC Guidance
- Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020
- MMWR/Medscape free CE credit on the updated 2020 latent TB infection treatment guidelines.external icon
Registration may be required. - Update on Recommendations for Use of Once-weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium Tuberculosis Infection
- Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection
Additional Resources
- CDC Medscape Commentary: Latent TB Infection Updated Treatment Recommendationsexternal icon
- USPSTF Latent Tuberculosis Infection: Screening Recommendationexternal icon
- The Journal of the American Medical Association (JAMA)external icon
- Bright Futures Recommendations for Pediatric Preventive Health Carepdf iconexternal icon
- Latent TB Infection in the United States – Published Estimates
- National Tuberculosis Controllers Association (NTCA) Testing and Treatment of Latent Tuberculosis Infection in the United States: Clinical Recommendationsexternal icon
CDC Resources for USPSTF Recommendations
- American Journal of Nursing: Tuberculosis: A New Screening Recommendation and an Expanded Approach to Elimination in the United Statesexternal icon
- Video: 5 Things to Know About TB
- Kelcie’s Story of LTBI Testing and Treatment
- CDC Messages and Resourcespdf icon
- USPSTF LTBI Recommendation: Statement from Dr. Phillip LoBue, Director, CDC’s Division of Tuberculosis Elimination
- Sample Communication Templates for Partners
- USPSTF Recommendation Statement: Screening for Latent Tuberculosis Infection (LTBI) in Adults (slide set)pdf icon
- Huffington Post: The End Game – Eliminating Tuberculosis In America by NCHHSTP Director Dr. Jonathan Merminexternal icon
- CDC Medscape Commentary: New Recommendations to Support Latent Tuberculosis Testingexternal icon
- The Lancet Infectious Diseases: Latent TB infection: the final frontier of TB elimination in the USAexternal icon
Social Media Graphics, Web Button and Infographics
Copy the code below to embed this image.(200×200)
Infographics
Fact Sheets
Providers
- The 12-Dose Regimen for Latent TB Infection Treatment: Fact Sheet for Clinicianspdf icon
- Treatment of Latent TB Infection: Maximizing Adherence
- Treatment Options of Latent Tuberculosis Infection
- Targeted Tuberculosis Testing and Interpreting Tuberculin Skin Test Results
- Frequently Asked Questions on the 12-dose regimen for Latent TB Infection for Providers
- Frequently Asked Questions on the 12-dose regimen for Latent TB Infection for Pharmacists
Patients
- Testing for Tuberculosis
- 12-Dose Regimen for Latent TB Infectionpdf icon
- Isoniazid-specific regimenpdf icon
- Rifampin-specific regimenpdf icon
- What You Need to Know About Your Medicine for Latent Tuberculosis (TB) Infection – Isoniazid and Rifapentinepdf icon
- 12-Dose Regimen for Latent TB Infection-Medication Tracker and Symptom Checklistpdf icon
- 4 Months Daily Rifampin Schedule for Latent Tuberculosis (TB) Infectionpdf icon
- 3 Months of Daily Isoniazid plus Rifampin (3HR)pdf icon
Page last reviewed: May 11, 2017
Content source: Division of Tuberculosis Elimination